The global non-invasive prenatal testing (NIPT) market size is projected to reach USD 13.16 billion by the end of 2028. The presence of several large scale companies will have a positive impact on the growth of the market in the upcoming years. According to a report published by Fortune Business Insights, titled, “Non-invasive Prenatal Testing (NIPT) Market, 2021-2028,” the market was worth USD 3.48 billion in 2020 and will exhibit a CAGR of 18.1% during the forecast period, 2021-2028.
List of Non-invasive Prenatal Testing
Providers Profiled in the Report:
- Illumina, Inc. (U.S.)
- YOURGENE HEALTH (U.K.)
- Natera (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- PerkinElmer Inc. (U.S.)
- Laboratory Corporation of America (U.S.)
- Eurofins LifeCodexx GmbH (Germany)
 |
Report Coverage-
This research report includes in-depth
information about the non-invasive
prenatal testing industry.
The data present in it is related to drastic changes in material usage, unique
product launches, and technological advancements. It offers dynamics based on various
factors, such as opportunities, challenges, drivers, and restraints. In
addition to that, it will deliver a complete insight from the supply side
respondents related to market share, distribution, and size.
Drivers &
Restraints-
Rising Number of Company Mergers and
Acquisitions to Have a Huge Impact on Market Growth
The report encompasses several factors that have contributed to
the growth of the overall market in recent years. Amongst them, the increasing
number of company collaborations has made the highest impact on the market
growth. In March 2019, for instance, Natera announced that it has formed a
strategic partnership with QIAGEN. Through this collaboration, the company will
develop breakthrough cell-free DNA assays. These companies will further
capitalize on QIAGEN’s GeneReader NGS System.
Such collaborations are aimed at advancing in the NIPT sector and more
companies will look to maximize the use of technologically advanced concepts.
Natera’s collaboration with QIAGEN is among the major company collaborations of
recent times that have had a major say on the growth of the non-invasive
prenatal testing market.
Read a Detailed Summary of This Report: https://www.fortunebusinessinsights.com/industry-reports/non-invasive-prenatal-testing-market-100998
COVID-19 Pandemic to Have a Minimal
Impact on NIPT Manufacturers
The COVID-19 pandemic has had an adverse effect on several
industries across the world. Several reputed companies operating in the
non-invasive prenatal testing industry are constantly keeping in touch with the
U.S. FDA to get to know detailed information about supply chain disruptions.
Also, research institutes are conducting many studies to determine the effect
of the coronavirus on births and pregnancies. SeraCare’s report, for instance,
declares that clinical testing laboratories and in-vitro diagnostics manufacturers
are working closely to determine the interference of SARS-CoV-2 infection on childbirths.
Regional Insights-
North America to
Emerge Dominant; Presence of Several Diagnostic Centres to Aid Growth
The report analyses the ongoing market trends across five major
regions, including North America, Latin America, Europe, Asia Pacific, and the
Middle East and Africa. Among all regions, the market in North America is
projected to emerge dominant in the upcoming years. The increasing penetration
of non-invasive prenatal testing will bode well for the growth of the regional
market. The increasing incidence of Down syndrome among babies, especially in
the United States will have a massive impact on the growth of the regional
market. The rising investments in the research and development of efficient
NIPT by large scale companies in this region will emerge in favor of market
growth. As of 2020, the market in North America was worth USD 1.79 billion and this value is projected to increase further in
the forthcoming years.
Competitive Landscape-
Key Players Aim to Develop New Tests
to Cater to High Consumer Demand Worldwide
The market for non-invasive prenatal testing is highly
consolidated with the presence of numerous companies. Most of them are
participating in the strategy of partnerships and acquisitions to cater to the
increasing demand from consumers. Some of the others are trying to conduct
extensive R&D activities to unveil new technologies in the field of
non-invasive prenatal testing.
Industry Developments:
July 2019: Invitae
announced that it will be acquiring Singular Bio, a company specializing in
single-molecule cell-free DNA analysis. The collaboration will be aimed at
developing non-invasive prenatal tests.
Read Press Release: https://www.fortunebusinessinsights.com/press-release/global-non-invasive-prenatal-testing-market-10207
No comments:
Post a Comment